search
Back to results

Directly Observed Therapy for Community-Released HIV+ Prisoners (Connect)

Primary Purpose

HIV/AIDS, Substance Abuse

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Directly administered antiretroviral therapy
Sponsored by
Yale University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV/AIDS focused on measuring HIV, AIDS, substance abuse, directly administered antiretroviral therapy, adherence, Substance Abuse and Dependency

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • HIV seropositive
  • 18 years of age or older
  • incarcerated for a minimum of 90days
  • living in New Haven or Hartford
  • currently on HAART or willing to begin HAART medications

Exclusion Criteria:

  • Not meeting inclusion criteria

Sites / Locations

  • Yale University-Yale Clinical Research
  • Yale University School of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

DAART

2

Arm Description

Group that will be observed daily taking their medications for a period of six months. Followed by the remaining six months of the intervention in which the subject will take medications on their own.

SAT (standard of care) group will take their medications as directed by their physicians for the period of one year.

Outcomes

Primary Outcome Measures

Virological success, defined as greater than 1 log HIV-1 copies/mL reduction or Viral load less than 400 copies/mL at the end of six months on the intervention.

Secondary Outcome Measures

DAART subjects will be more likely to make primary HIV care visits than those receiving SAT.
Lower rate of recidivism and to illicit drug use

Full Information

First Posted
November 5, 2008
Last Updated
August 18, 2014
Sponsor
Yale University
search

1. Study Identification

Unique Protocol Identification Number
NCT00786396
Brief Title
Directly Observed Therapy for Community-Released HIV+ Prisoners
Acronym
Connect
Official Title
Directly Observed Therapy for Community-Released HIV+ Prisoners
Study Type
Interventional

2. Study Status

Record Verification Date
August 2014
Overall Recruitment Status
Completed
Study Start Date
July 2004 (undefined)
Primary Completion Date
December 2010 (Actual)
Study Completion Date
December 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this study is to develop effective interventions for HIV-infected prisoners who are released to the community. The intervention that we will study will be directly observed therapy (DAART/DOT) and we will compare this to the current standard of care that involves self-administered therapy (SAT). All subjects will get transitional case management and all subjects with a prior history of opiate dependence will be offered opiate substitution therapy (buprenorphine or methadone). Hypotheses: At the end of six months those receiving DAART will have a higher level of adherence to HAART as compared to the SAT group. The DAART Intervention will result in subjects having lower viral loads and higher CD4 counts as compared to the SAT group. At the end of six months, the DAART group will have a lower rate of recidivism to jail/prison as compared to the SAT group. Over the year, the DAART group will be more likely to make repeated primary HIV care visits than the SAT group.
Detailed Description
Any individual that is HIV positive and incarcerated for at least a period of 90 days and on antiretroviral medications would be referred to the study by the medical staff of the incarceration facilities prior to release or within 30 days of release an individual would be able to self refer. Subjects would be screened and consented and interviewed prior to their release from incarceration, on their day of release, and monthly for a period of one year. At the time of their day of release interview, subjects are randomized to either the intervention DAART group or the standard of care SAT group. All subjects would be assessed and offered opiate substitution therapy if there was a prior history of opiate dependency as a means of relapse prevention. Subjects in DAART would be seen everyday for a period of six months by a team of research assistants who observe the subjects taking their medications, and their last six months would be done as standard of care. Standard of care SAT subjects would continue to take their medications on their own as prescribed. All subjects would be interviewed monthly and quarterly would have laboratory blood tests completed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV/AIDS, Substance Abuse
Keywords
HIV, AIDS, substance abuse, directly administered antiretroviral therapy, adherence, Substance Abuse and Dependency

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
151 (Actual)

8. Arms, Groups, and Interventions

Arm Title
DAART
Arm Type
Experimental
Arm Description
Group that will be observed daily taking their medications for a period of six months. Followed by the remaining six months of the intervention in which the subject will take medications on their own.
Arm Title
2
Arm Type
No Intervention
Arm Description
SAT (standard of care) group will take their medications as directed by their physicians for the period of one year.
Intervention Type
Behavioral
Intervention Name(s)
Directly administered antiretroviral therapy
Intervention Description
Daily observation of subjects taking their HIV medications
Primary Outcome Measure Information:
Title
Virological success, defined as greater than 1 log HIV-1 copies/mL reduction or Viral load less than 400 copies/mL at the end of six months on the intervention.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
DAART subjects will be more likely to make primary HIV care visits than those receiving SAT.
Time Frame
12
Title
Lower rate of recidivism and to illicit drug use
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: HIV seropositive 18 years of age or older incarcerated for a minimum of 90days living in New Haven or Hartford currently on HAART or willing to begin HAART medications Exclusion Criteria: Not meeting inclusion criteria
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Frederick L Altice, MD
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gerald Friedland, M.D.
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yale University-Yale Clinical Research
City
Hartford
State/Province
Connecticut
ZIP/Postal Code
06106
Country
United States
Facility Name
Yale University School of Medicine
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06510
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
22101218
Citation
Saber-Tehrani AS, Springer SA, Qiu J, Herme M, Wickersham J, Altice FL. Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community - a potential conduit to improved HIV treatment outcomes. Contemp Clin Trials. 2012 Mar;33(2):436-44. doi: 10.1016/j.cct.2011.11.002. Epub 2011 Nov 12.
Results Reference
background
PubMed Identifier
20024753
Citation
Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care. 2009 Aug;21(8):976-83. doi: 10.1080/09540120802657555.
Results Reference
background
PubMed Identifier
20177974
Citation
Springer SA, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urban Health. 2010 Jul;87(4):592-602. doi: 10.1007/s11524-010-9438-4.
Results Reference
background
PubMed Identifier
22879972
Citation
Meyer JP, Qiu J, Chen NE, Larkin GL, Altice FL. Emergency department use by released prisoners with HIV: an observational longitudinal study. PLoS One. 2012;7(8):e42416. doi: 10.1371/journal.pone.0042416. Epub 2012 Aug 3.
Results Reference
background

Learn more about this trial

Directly Observed Therapy for Community-Released HIV+ Prisoners

We'll reach out to this number within 24 hrs